Jefferies Downgrades CureVac to Hold From Buy, $5 Price Target

Published on 06/13/2025 at 07:22

MT Newswires

This article is reserved for members

Unlock the article: REGISTER NOW!

100% Free Registration

Already a customer? Log In

Latest news about CureVac N.V.

CUREVAC : Pipeline pruning’s nasty effect	Jul. 14
CureVac N.V. - Shareholder/Analyst Call	Jul. 01
UBS Downgrades CureVac to Neutral From Buy, Adjusts Price Target to $5.50 From $12	Jun. 26	MT
CureVac N.V. Approves Board Appointments, Effective June 24, 2025	Jun. 23	CI
CureVac agrees to pay Biontech termination fee Of $43.8 mln under specified circumstances	Jun. 16	RE
Jefferies Downgrades CureVac to Hold From Buy, $5 Price Target	Jun. 13	MT
CUREVAC : Downgraded to Neutral by Jefferies	Jun. 13	ZD
Health Care Climbs Amid Deal Activity - Health Care Roundup	Jun. 12	DJ
Sector Update: Health Care Stocks Higher Late Afternoon	Jun. 12	MT
Deals of the day-Mergers and acquisitions	Jun. 12	RE
BioNTech takes over CureVac in $1.25 billion all-stock deal among COVID rivals	Jun. 12	RE
Top Midday Gainers	Jun. 12	MT
Sector Update: Health Care Stocks Advance in Afternoon Trading	Jun. 12	MT
Sector Update: Health Care	Jun. 12	MT
German Stocks Flash Red Amid US Tariff Concerns	Jun. 12	MT
Top Midday Stories: Boeing Shares Fall After Air India Plane Crash; Oracle Q4 Results Top Expectations	Jun. 12	MT
Deals of the day-Mergers and acquisitions	Jun. 12	RE
BioNTech takes over CureVac in $1.25 billion all-stock deal among COVID rivals	Jun. 12	RE
Sector Update: Health Care Stocks Lean Lower Premarket Thursday	Jun. 12	MT
Sector Update: Health Care	Jun. 12	MT
US Equity Futures Decline as Trump Talks Tough on Trade	Jun. 12	MT
BioNTech to Acquire CureVac in $1.25 Billion All-Stock Deal	Jun. 12	MT
German economy ministry says it supports BioNTech/CureVac transaction	Jun. 12	RE
Top Premarket Gainers	Jun. 12	MT
BioNTech, CureVac Agree to All-stock Purchase Deal	Jun. 12	MT